-

Telesair Secures Strategic OUS License Agreement for Next Generation Respiratory Technology

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., an innovator of next generation respiratory care, announced today that it has closed a license agreement with a leading global medical device manufacturer.

Per the agreement, Telesair will utilize its patented technologies to develop a new respiratory platform for use initially only in an outside the United States (OUS) geography. In exchange, Telesair will earn a multi-million dollar upfront payment, a multi-million dollar milestone upon completion of its offering, and ongoing royalty payments based on sales of the device.

“This partnership represents validation of Telesair’s technical capabilities to produce advanced respiratory technologies not currently on the market today,” said Telesair CEO, Bryan Liu. “Telesair management’s ability to identify unmet needs in the market and develop technology to address those needs will create a continuum of respiratory care that extends from better managing patients in the hospital through facilitating an earlier transfer of patients to lower cost settings such as the home. We have one of the best R&D teams in the space, and with our technological innovations, we will continue to develop our own pipeline of proprietary solutions to address a wide array of diseases in the multi-billion dollar global respiratory market.”

Telesair, Inc. is a Southern California based, high-growth company that is developing breakthrough solutions to help move patients from hospital to home sooner by providing compact, mobile respiratory care solutions to hospitals, long-term care and skilled nursing facilities, rural health providers, and in the homecare setting. Led by respiratory veterans in both R&D and commercialization, the company has developed a next-gen, advanced respiratory treatment system platform based on state-of-the-art sensor fusion technologies and innovative pneumatics. Telesair’s solutions are designed to elevate the existing standard of care by improving outcomes for patients and the health system. Learn more at Telesair.com.

Contacts

Media Contact: Paul Williams, MediaLine Communications
paul@medialinecommunications.com, 310/569-0023

Investor Contact: Briani Allen, Telesair, Inc.
invest@telesair.com

Telesair, Inc.


Release Versions

Contacts

Media Contact: Paul Williams, MediaLine Communications
paul@medialinecommunications.com, 310/569-0023

Investor Contact: Briani Allen, Telesair, Inc.
invest@telesair.com

More News From Telesair, Inc.

Telesair Receives FDA Clearance for Bonhawa High Flow Oxygen Therapy System

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., a technology leader in the respiratory industry, announced today that it has received FDA clearance to market its Bonhawa High Flow Oxygen Therapy (HFOT) system, designed to enhance the treatment of patients with respiratory insufficiency. Bonhawa is now the only purpose-built high flow system to receive both the CE Mark/European Medical Device Regulation and FDA 510(k) clearance. Bonhawa gives healthcare providers and their patients in the US an...

Telesair Receives CE Mark for Bonhawa High Flow Oxygen Therapy System

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., an innovator of next generation respiratory technology, announced today that it has received CE (Conformité Européenne) Marking under the European Medical Device Regulation for its Bonhawa High Flow Oxygen Therapy (HFOT) system for use in the treatment of patients with respiratory insufficiency. The Bonhawa HFOT is one of the first respiratory therapeutic devices from a US based company to receive CE Mark under the new European Medical Device Reg...

Telesair’s Bonhawa High Flow Oxygen Receives Approval from Thai FDA

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., an innovator of next-generation respiratory care, and JPP Care, a leading Thai distributor of respiratory devices, jointly announced today that Telesair’s Bonhawa High Flow Oxygen Therapy (HFOT) system has been approved by Thailand’s Food and Drug Administration (Thai FDA) for use in the treatment of patients with respiratory insufficiency. The light and compact Bonhawa HFOT device features an extended flow range up to 80 L/pm, a simple disinfect...
Back to Newsroom